D R. SCHROEDER: Most of us have
been confused by the varying and conflicting reports in the literature and at meetings concerning the effectiveness or ineffectiveness of modern antihypertensive drugs and their place in the treatment of arterial hypertension. During the past five years we have been given a number of agents which appear to counteract to varying degrees the general vasospasm with which hypertension is associated, but all of which have produced toxic side effects or serious manifestations of their primary actions. The purpose of this conference is to attempt a clarification of the present situation in regard to such agents and similar ones being developed, and to consider when they should and should not be used. Perhaps it would be well to begin with a short resume of the pharmacology of the more important of them. Dr. Perry, you might discuss the Rauwolfia alkaloids, protoveratrine and its relatives, ganglionic blocking agents and hydralazine. That order, progressing from a central encephalic locus of action to a peripheral one at the vascular smooth muscle, is a good one. Let us confine ourselves to pure compounds.
DR. PERRY: The first three act primarily upon autonomic nerves. Reserpine, an alkaloid in the whole root of Rauwolfia serpentina, is a slowly acting corticohypothalamic depressant which produces partial nervous sympatholysis by inhibiting impulses to the sympathetic center. The extreme flatness of the dosageresponse curve and the relatively weak action obviate the hypotensive episodes which com- plicate the use of other more potent vasoactive drugs. Unpleasant side effects include nasal 98 obstruction, diarrhea, obesity, anxiety, nightmares and insomnia. Activation of peptic ulcers and colitis has been seen. Of much greater import, however, is an occasional extreme psychotic depression with suicidal tendencies. The limited antihypertensive effect may partially explain the failure to observe tolerance.
Veratrum alkaloids, of which protoveratrine is a purified principle, influence vasomotor centers in the medulla via the vagal and the carotid bifurcation receptors resulting in parasympathetic overactivity. They appear to stimulate the depressor nerves, thus causing a fall in blood pressure. The small margin of safety between therapeutic and toxic amounts makes dosage critical. The side effects are bradyeardia, hypotension, nausea and vomiting. The rapid appearance of tolerance limits the ability of these agents to maintain continuous normotension.
Ganglionic blocking agents, of which hexamethonium and pentolinium salts are examples, diminish all nervous transmission at the autonomic ganglia. Their potency may initially produce acute hypotensive episodes which respond to a supine position. In general, the beneficial effects are those of sympatholysis, while the undesirable effects are those of parasympatholysis and include failure of visual accommodation, dry-mouth, constipation and difficulty with urination. The considerable tolerance, which is the rule when these agents TREATMENT OF HYPERTENSION WITH MODERN DRUGS creted and therefore must be given at regular intervals in order to maintain minimal variation in blood levels.
A PHYSICIAN: If your purpose is to block the sympathetic portion of the autonomic nervous system and many of the undesirable side effects result from tampering with the parasympathetic portion, why do you not use true sympatholytic agents? DR. PERRY: Unfortunately with the known sympatholytic compounds, a dose, sufficient to produce an adequate hypotensive effect, is intolerable for any extended period, primarily because of tachycardia. Sufficiently potent new ones may be found which might replace the blocking agents.
Let us return to the pharmacology of hydralazine which is an extremely reactive chemical and a most valuable agent. Only a weak sympatholytic action can be demonstrated. It is quite rapidly altered in the body and probably undergoes more than one reaction. In vivo, hydralazine apparently binds sulfhydryl compounds since the combination can be isolated from the urine. In vitro, therapeutic levels of this drug combine with physiologic concentrations of pyruvate and other carbonyl reagents. Experimentally, it acts on constricted vascular smooth muscle. It is a true renal vasodilator; with its relatives, it has the unique property of increasing blood flow in the face of a lowered blood pressure. Isolated coronary arteries are also dilated. Our current ideas on its probable mode of action, however, involve the metal binding capacity of hydralazine, since it seems to have only this property in common with a group of non-neurogenic antihypertensive agents, such as azide, nitroprusside and thiocyanate. Since it can act as an antienzyme, perhaps an enzymatic reaction rate is altered by interference with metallic coenzymes, resulting in a changed irritability of vascular smooth muscle.
A PHYSICIAN: Do the other hydrazides, particularly the antituberculous agents, isoniazid and iproniazid, have similar metal binding powers and antienzyme activities? DR. PERRY: They do. The relative strengths of their chelating capacities for the various transition metals is somewhat different for each compound. The antienzyme action of each also differs and may be quite specific.
There is no good evidence that the usually unequivocal but seldom dramatic antihypertensive effect of hydralazine is mediated via the central nervous system, although a central action has been demonstrated. It is a prolonged dilator, even on isolated vascular beds. Its antihistaminase activity, which may or may not involve a metal, partially explains some of the side effects, particularly, nasal obstruction and headache. In addition, tachycardia, anorexia, nausea and vomiting may occur. Tolerance is common when it is used alone, but seldom appears when a nerve-acting drug is added.
A is not yet available. Hypertension, however, is associated with a high incidence of vascular accidents, and our experience suggests that lowering the intra-arterial pressure diminishes such episodes in patients who have previously experienced one or more attacks.
As to the chance of harming the patient with drug therapy, it is very small if minimal precautions are observed. We have recognized no irreversible reaction to the drugs in the last 36 months and the rare prior cases occurred when control was poor and conditions of treatment not ideal. Hence we feel that permanent harm will not come to anyone who continues to take drugs under supervision. Discontinuation, on the other hand, may result in a rebound hypertension followed by vascular accident or progressive renal failure.
A comparison of the advantages and disadvantages of lowering an elevated blood pressure, per se, suggests that the value almost always outweighs the risk, since both increase proportionately to the severity of the disease. Undesired side effects, which plague all forms of treatment, increase the danger only slightly. With a combination of hydralazine and methonium therapy carefully administered, the overall hazard is small. Initially, drug-induced hypotension is not rare. Although alarming, this clinical picture must be sharply differentiated from shock, by the presence of peripheral vasodilatation and normal cardiac rate. In our experience, such episodes are transient; moreover, there has been no accompanying evidence of myocardial anoxia, and the syncope which accompanies cerebral ischemia responds readily to the supine position. No permanent damage, resulting from clot formation or oxygen deficit, has been observed by us in well treated patients. Drug-induced parasympatholysis may lead to obstruction of hollow viscera. Parasympathomimetic drugs, catheterization or even prostatectomy may be needed to control urinary retention in the male with prostatism. We have never seen paralytic ileus result from methonium therapy. With laxatives, an intelligent, cooperative individual can control his bowels, which pose the most stubborn and persistent problem. In particularly recalcitrant cases, gastrointestinal exposure to the autonomic blocking agent can be reduced by parenteral administration. The combination of constipation and renal decompensation leads to increased methonium absorption and decreased excretion, a condition which is selfperpetuating, since an accumulation of drug further reduces both gastrointestinal motility and glomerular filtration pressure. We treat the side effects as they appear.
Temporary discomfort can be expected after any considerable alteration in hemodynamics. For weeks or months after the initiation of drug therapy, considerable inconvenience is inevitable. The altered hemodynamics and the depressed nervous transmission are particularly marked for patients with severe stages of hypertension. Their blood pressures are very high and large doses of blocking agents are required. They, therefore, have all the symptoms of parasympatholysis plus anorexia and mental depression added to their woes. This would indeed be a high price to pay indefinitely for normotension, but fortunately the unpleasant side effects diminish and, except for masculine impotence, all finally vanish, although their complete disappearance usually takes many months.
A better way than this involved, sometimes unpleasant, and inconvenient method for the control of hypertension is needed, but none has yet been devised which consistently affects the severe stages of the disease. In reality, such therapy is no Although its hypotensive effect is usually slight for those whose blood pressure is labile and rarely elevated (except in a physician's office), it is often sufficient to sustain normotension. The amount taken is not critical since a wide range of doses is effective without being toxic. For those with more severe hypertension and a normal blood pressure only during sleep, induced by heavy sedation, it is necessary to add hydralazine to achieve normotension. A hypotensive effect is usually obtained but is seldom abrupt; hence, the intake does not have to be finely adjusted. Relatively small quantities of the order of 250 mg. per day are used, since they generally suffice and since they obviate most of the delayed reactions. To lower fixedly elevated diastolic pressures, a ganglionic blocking agent is added to hydralazine and reserpine in a dose adequate to produce the desired result. The action of this drug is sufficiently dramatic that dosage must be carefully regulated. To minimize the wide fluctuations in blood pressure and also to prevent the very frequent tolerance to methonium compounds, it is often necessary to increase the hydralazine intake. Reserpine may lessene th required dosage of other drugs, even if alone it does not cause a significant change in blood pressure, and it frequently helps to correct methonium constipation. Perhaps the following case will indicate the method of therapy and the result achieved in severe hypertension: L. L., a white male, was 34 years old when he was first seen in November, 1951 because of headaches for three months. At that time fundoscopic examination revealed hemorrhages and exudates without papilledema. His blood pressure was 250/ 140 mm. Hg and his heart was enlarged, although his lungs were clear and there was no pedal edema. He excreted only 5 per cent of intravenously injected phenol red within 30 minutes, and 2 plus albuminuria was present, without nitrogen retention. Hexamethonium chloride every four hours by mouth was begun in increasing amounts until his supine blood pressure, which had not changed with hospital rest, fell to an average of 180/110 mm. Hg,* with occasional readings of 140/90 mm. At that time, the size of his hexamethonium dosage was made contingent on the level of his blood pressure. Oral hydralazine was then added and the fluctuations of blood pressure became smaller. He was maintained normotensive by 0.15 Gm. hydralazine, five times a day, with a simultaneous variable intake of hexamethonium chloride as follows: 1 Gm. for any sitting systolic pressure over 140 mm. Hg, 0.50 Gm. for pressures between 130 and 140 mm. and 0.25 Gm. for pressures between 120 and 130 mm. He was then given a sphygmomanometer and taught to use it. After three weeks in the hospital, he returned to work immediately, although constipation, dry-mouth and some amblyopia persisted. Within two months he was free of symptoms. He has since continued his work as farmer and truck driver. About four years after beginning therapy, he is taking 0.10 Gm. of hydralazine and an average of 0.12 Gm. of hexamethonium chloride, five times a day, to For four months he took approximately this amount of medication regularly and then was able to return to work; his mean sitting systolic pressure was 155 mm. Hg. Feeling that he was cured, he then discontinued treatment. His final readmission was 43 days later. Again he was in marked respiratory distress. His blood pressure was 200/140 mm. Hg. Fundoscopic examination revealed blurred optic discs without frank papilledema, but there were fresh hemorrhages and exudates. The signs of cardiac failure were more marked than on previous hospital entries. The nonprotein-nitrogen level was 105 mg. per 100 ml. of blood. An attempt was made to recontrol his blood pressure with hydralazine and pentolinium tartrate by giving increasing parenteral doses. After 4 Gm. of pentolinium tartrate and 2 Gm. of hydralazine within a 24 hour interval had no significant effect, he was given 0.5 Gm. of each intravenously in the same syringe during a period of three minutes. The resultant fall in diastolic pressure from 145 to 130 mm. Hg lasted only for seven minutes. Thereafter his uremia rapidly progressed and he died of renal failure two weeks after hospitalization.
DR. SCHROEDER: One sees reports in which patients were alternatively given placebos and these drugs. The usual result of such studies has been to indicate that the drugs are relatively ineffective. We have noticed the same phenomenon ourselves when the drugs were discontinued or when placebos were used. I know of no better way to produce tolerance than to give these agents intermittently. It is essential to therapy to apply even continuous therapeutic pressure, increasing to the point where the desired results are achieved without intermittency or periods of discontinuation. This phenomenon is not at all understood but it may be likened in a broader sense to that of bacterial resistance to chemotherapeutic agents used intermittently in an infection. There appears to be something about normotension, when achieved with these drugs, which carries with it a favorable outcome insofar as the continued action of the drugs themselves is concerned. Two, three or even many times the original dose may become necessary when patients are taken off and put back on. One of the most prevalent factors in producing this curious kind of tolerance to the agents lies in the insecurity of the physician when he first sees the blood pressure falling to normal levels from very high ones and the patient has symptoms associated with this fall. He then becomes worried and discontinues the drug; the blood pressure soon returns to its previous levels and he finds it extremely difficult to control the hypertension from then on. On the other hand, we have not observed tolerance developing when these drugs were properly used and normotension or a reasonable facsimile thereof was achieved for long periods of time in a fresh, untreated case.
DR Hg. She was discharged from the hospital with this maximum dosage to be taken according to our usual regimen in which the amount of blocking agent is determined five times a day by reading the sphygmomanometer. Within a month the side effects of therapy had disappeared and she was leading a normal life. Gradually and automatically her hexamethonium intake decreased along with her blood pressure, and by September 1952, she only required 0.25 Gm. per day since her sitting systolic readings were almost invariably less than 130 mm. Hg and frequently below 120 mm. By this time we had reduced her daily dosage of hydralazine to .05 Gm. With cooler weather, however, her blood pressure rose to 150/100 mm. Hg, thus automatically increasing her mean hexamethonium requirement to more than 1 Gm. per day. By April of 1953, she needed no further hexamethonium ion. Shortly thereafter hydralazine was also discontinued. After an interval of three weeks her normal mean systolic pressure slowly rose to 155 mm. Hg, reaching 180 mm. on one occasion. Subsequently, small amounts of reserpine rapidly reduced her blood pressure to 125/75 mm. Hg. After discontinuation of this alkaloid, normotension persisted for two months without any antihypertensive agents. When it again increased a briefer course of reserpine was followed by a more extended period of strict normal blood pressure with no drug intake, which has continued seven months to date.
A PHYSICIAN: YOU mentioned some evidence that treatment of severe hypertension prolongs life and avoids disability. Would you elaborate? DR. PERRY: The "malignant" stages of hypertension as previously defined are uncommon, but they serve to show the efficacy of therapy. Several series of patients with such an accelerated phase of the disease have been followed, indicating the dire prognosis without treatment. In the most recent compilation, Schottstaedt and Sokolow found that in the absence of therapy the average life expectancy was nine months, with almost half of the subjects succumbing in 90 days and only 15 per cent surviving for two years. Before effective drugs were available, Smithwick demonstrated a significant reduction in mortality among patients subjected to surgical sympathectomy as compared with a similar unoperated group. More recently, Smirk has shown a similar improved prognosis following treatment with autonomic blocking agents alone. Among 64 of our patients who were initially in the "malignant" stages of hypertension and who have regularly taken oral hydralazine and hexamethonium chloride over a two to four year period, 54 are alive and 51 are back at gainful occupations. It is difficult to see how such figures can be discounted or how a case history like the following can be ignored.
I. M., a Negro woman, was 47 years old when we first saw her in August, 1951. Two years previously she became totally incapacitated by intermittent but increasingly severe bouts of left ventricular insufficiency; and three years before that, she was denied life insurance because of albuminuria and hypertension. When she entered Barnes Hospital, she had long been unable to lie down, despite salt restriction and full digitalization. Fundoscopic examination revealed hemorrhages, exudates and papilledema. The other significant physical findings included bilateral pleural effusions, cardiomegaly, hepatomegaly and pedal edema. Her renal status was defined by 2 plus albuminuria, a normal blood nonprotein-nitrogen level, and 5 per cent excretion of intravenously injected phenol red in 15 minutes. Hydralazine and hexamethonium therapy according to the usual regimen dramatically lowered her mean blood pressure to less than 140/90 mm. Hg, where it remained for two years during which she regularly took her medication. During this interval, she was entirely free of symptoms including side effects of the drug and she daily worked 8 to 10 hours in a restaurant. Her ocular fundi became grade I (Keith-Wagener), her albuminuria disappeared and her cardiac size reverted to normal. Despite discontinuation of her digitalis and salt restriction, there was no recurrence of heart failure and she was accepted for insurance by the company which had rejected her seven years earlier. He was readmitted after seven weeks because of reappearance of both right and left ventricular failure. The changes in his physical examination were confined to the ocular fundi and included hemorrhages, exudates and papilledema. The only significantly altered laboratory finding was a nonprotein-nitrogen level of 109 mg. per 100 ml. of blood. Cautiously given hexamethonium chloride resulted in a fall in his blood pressure from its admission value of 240/140 to 190/115 mm. Hg. There was an immediate improvement in the signs and symptoms of cardiac decompensation and a concomitant rise in his nonprotein-nitrogen to 160 mg. per 100 ml. of blood. Maintenance of this blood pressure for a few days was accompanied by a fall in the azotemia to its admission level. Therefore the blood pressure was further slowly lowered to 170/100 mm. Hg and this was followed by a second increase in the nonprotein-nitrogen level to 125 mg. per 100 ml. which then gradually declined to less than 50 mg. where it remained. At the same time the last evidences of cardiac failure vanished. After almost two months of hospitalization, he was discharged with this minimal azotemia and compromise blood pressure. His medication was taken by mouth five times a day and consisted of a constant dose of 0.10 Gm. hydralazine and a simultaneous variable dose of hexamethonium chloride averaging 0.49 Gm. Unfortunately he discontinued his regimen because of absence of symptoms and a month later died of cardiac failure, a few hours after his final readmission to the hospital.
A PHYSICIAN: YOU said you had never seen a patient really resistant to these drugs. That may be so, but what is your actual experience, taking into account all of the factors involved, cooperation, side effects, late toxicity, etc.? DR. PERRY: On the whole, it is good. About 80 per cent of our patients with severe hypertension control their systolic pressures at levels of 160 mm. Hg or below in four readings out of five. Few patients who need treatment cannot be encouraged by the physician to weather successfully the initially rigorous regimen and achieve lasting benefit. Private patients fare better than ward ones, and white patients better than Negroes. We do better than house officers, perhaps because we persist in treatment and handle side effects as they appear. We have an impression that the hardest therapeutic problems, barring azotemia, occur in men from 40 to 60 years old with "benign" hypertension and tortuous aortas. The next most difficult are the women with extreme emotional lability; partial autonomic blockade does not prevent spikes of blood pressure, induced by emotion and troughs, following relaxation; reserpine helps. A comparatively easy problem is the young "malignant" hypertensive without nitrogen retention.
A PHYSICIAN: Although there are some reports of very favorable results following these drugs, there are many who feel that drug therapy has little to offer hypertensive patients. Can you explain this discrepancy? DR. PERRY: The conflicting reports regarding these drugs are disturbing. First, however, the areas of agreement should be emphasized. Although different investigators have used different drugs in different ways, those who have used them in adequate doses and according to logical schedules agree that the progress of severe hypertension has been halted or markedly retarded in many cases. As has been previously discussed, our definite claims of prolonging life have been confined to that small group of patients with "malignant" hypertension and a desperate immediate prognosis. I know of no contrary claims by an investigator using similar dosages for similar patients. Beyond the area of agreement, there are considerable areas of disagreement as to the efficacy of medical therapy. Several factors must be jointly responsible for the differences of opinion. The difficulty in evaluating the severity of human hypertension is not to be underestimated. Many physicians who do not believe in antihypertensive therapy insist that its good results are found only in those patients who are mistakenly classified as having bad hypertension. When a physician's skepticism as to the value of therapy is combined with an excessive fear as to its potential risk, he usually resorts to doses of insufficient size and frequency. This is unfortunate, since partial treatment often has no significant effect, and yet antihypertensive agents are commonly abandoned on the basis of such an inadequate trial. Unjustified expectations by the patient may be at fault. Many are not helped by drugs because they expect too much and hence they are unwilling to tolerate temporary unpleasant side effects. Too many physicians are alarmed to see a sphygmomanometer in the hands of the public. Whatever the theoretic disadvantages of giving a blood pressure machine to a patient, the dangers of not doing so are very real. Ganglionic blocking agents are potent drugs. Sufficient must be given to achieve the desired antihypertensive effect, but hypotension-producing excesses should be avoided. The most satisfactory way to do this on a chronic basis involves giving the patient a sphygmomanometer and teaching him how to use it. We were fortunate in first giving the combination of hydralazine and hexamethonium chloride to four "malignant" hypertensive subjects, including the subject of the fourth case report, who were obviously rapidly deteriorating. To see three of these leave the hospital and return to gainful occupations was sufficient to counteract several succeeding failures.
A PHYSICIAN: Are patients not made neurotic when they are taught to determine and record their own blood pressures? DR. PERRY: I have never seen a patient, who had achieved normotension, made nervous or neurotic by taking his own blood pressure, although I have seen a few who became tired of the routine and stopped it. The situation seems analogous to a diabetic testing his own urine. Elevated blood pressure is not alarming when it can be rapidly and safely lowered to any desired level. In fact, observing an elevated pressure fall following a pill instills a sense of security. It is true, of course, that they become as "blood-pressure conscious as are diabetics 'sugar conscious."
A PHYSICIAN: What type of patient would you not treat with these modern drugs? DR. SCHROEDER: There are probably only three types of patients who do badly. The first is the uncooperative individual who refuses to take pills at stated intervals and who will not or cannot learn to take his own blood pressure.
When the disease is serious or in "malignant" stages, giving potent drugs intermittently and ineffectually is tantamount to allowing rapid progression with eventual fatal outcome. In such cases, one has recourse only to surgical sympathectomy in an attempt to prolong life. The second kind of patient is the one with severe azotemia. We have 16 individuals with moderate nitrogen retention who are alive after three years; however, when frank uremia or marked azotemia is present, these drugs are almost valueless. Although they may relieve the workload of the heart and avoid pulmonary edema, the inexorable course of the disease is not halted. Whenever nitrogen retention is present, it is possible to lower the blood pressure beyond the point where adequate glomerular filtration through damaged kidneys can occur. In such situations, particularly after cardiac decompensation has occurred, it may be difficult to steer between the Scylla of heart failure and the Charybdis of renal failure, but by careful attention to detail it can be done. The third kind of case which should not be treated is the person with systolic hypertension on an atherosclerotic basis who has a normal diastolic pressure. These drugs act merely on excessive vasospasm. They do not act on hard pipes. Atherosclerotic individuals with a blood pressure of say 200/80 mm. Hg may achieve a blood pressure of 140/30 mm. Hg, but such a hemodynamic situation is hardly compatible with a good state of health. We are treating vasospasm and thereby affecting the general health of the patient. We are not treating a number.
A PHYSICIAN: What kind of patient is apt to respond to reduction of sodium in the diet? DR. SCHROEDER: In our experience the best responses to sodium reduction are in women with central obesity, some disturbance of their generative organs, a history of a rapid gain in weight and low sodium or chloride concentration in sweat. So far nine of these women have come to autopsy or have been operated upon, and all but one have shown adrenal cortical adenomata; the other had pituitary basophilia. These patients apparently form excessive amounts of salt-retaining hormone and may represent a variation of primary aldosteronism. In general, we use hydralazine and methonium compounds since they do respond to these drugs, although some appear resistant at first. We, therefore, rarely need sodium restriction in them.
A PHYSICIAN: Why do you not use sodium restriction in all cases? DR. SCHROEDER: Not only is it very inconvenient for the patient but there may also be an element of danger to it. When hydralazine is being given restriction of sodium in the diet may result in the "low-salt syndrome" or salt depletion in some patients. Apparently, hydralazine is a salt losing agent for kidneys that already show a tendency to lose salt, as hypertensive kidneys may. We have seen sodium depletion occur often enough to be thoroughly aware of its dangers when hydralazine is being employed. A PHYSICIAN: What about the treatment of hypertension in pregnant women? DR. SCHROEDER: I think that these cases must be divided into two types. First, in hypertensive women who become pregnant there is no contraindication to treatment. We have had very little experience with pregnancy in previously hypertensive women who were on these drugs, inasmuch as most of our patients are in the older age groups. Having frequently observed the initially successful therapy become increasingly less valuable, we searched for a possible explanation. The most reasonable suggests that after human hypertension has exceeded a certain degree of severity, it is rarely of purely neurogenic origin.
Ordinarily, there is a renal component as well. Our present concept is that hydralazine counteracts the renal factor, whatever it may be; whereas ganglionic blocking agents affect the autonomic nervous system, or neurogenic factor. ous system is overactive in arterial hypertension, three of the four types of drugs which have been mentioned act upon the autonomic nervous system. While it is possible that a normal tonus of the sympathetic nervous system is present in hypertension, the evidence is to the contrary. We have not time to list the evidence which, although indirect, points to overactivity. Let us say, then, that certain persons in the population have the ability to react to stress by vasospasm, either because of inherited or developmental traits. These persons may show a positive cold pressor test even though they are normotensive. As has been well worked out by Hines, many of them develop hypertension 10 or 20 years later. If this is so, a certain proportion of the population is predisposed to hypertension. It is only through nervous mechanisms that these reversible reactions can take place and one must assume that the sympathetic system plays the major role. Now the crux of the whole matter of pathogenesis, the "64 dollar question," seems to be: What factor or factors convert temporary intermittent vasospasm into permanent vasospasm? From epidemiologic studies, it would appear that there may be something in our civilization which tends eventually to convert reversible neurogenic vasospasm into irreversible or permanent vasospasm. In view of the tremendous amount of work on the kidney and its relation to sustained hypertension in animals and man, our suspicions are naturally directed to that organ. However, it has been shown conclusively, both experimentally and clinically, that organic renal arteriolar disease follows and does not precede the development of chronic hypertension. In dogs, the lesions may not appear until the fourth or fifth year of sustained hypertension. Therefore, we cannot implicate an organic renal basis. What other basis is there? We may look upon certain renal enzymatic mechanisms as being possibly affected by some exogenous material in civilized areas. Our suspicions became naturally aroused when it dawned upon us several years ago that all of the agents used to treat hypertension had in common only the ability to bind trace metals. Hydralazine was found by Dr. Perry to do this; thiocyanate is a commercially useful material for purification of ill ores; nitroprusside, 2, 3-dimercaptopropanol (BAL), and certain other mercaptans are specifically depressor in animals; sodium azide has a similar rather transient effect; 8-hydroxyquinoline and ethylenediamine tetra-acetate are antihypertensive in rats; and certain thiopseudoureas and thiosemicarbazide have this common property. All appear to act specifically upon hypertension, either experimental, clinical, or both. The discovery by Tipton and her associates of large amounts of presumably abnormal trace metals in American human tissues has led to considerable speculation and to some experimental work. The startling finding of Tipton and her co-workers was the presence of an enormous amount of cadmium in the human kidney, up to 33 mg. per kilogram. Cadmium did not appear in several infants, was there in smaller quantities in an older child, but was present in all adults studied. We do not know how it got there, but its concentration was half that of essential zinc. Truly it appears that trace metals may be involved in hypertension and the best lead we know of lies in their removal from the body by better chelating or binding agents.
A that no agent acting solely upon autonomic nerves can ever be more effective than total sympathectomy. Therefore, newer ganglionic blocking agents may be more readily absorbed, act more on sympathetic than on parasympathetic functions, act for longer intervals and more evenly, produce fewer side effects, be more potent on a weight for weight basis and be preferred to the older, time tested drugs. While the effects of their use in milder stages of the disease may be excellent, it is unlikely that they can do better than permanent surgical removal of nerves. Very long acting sympatholytic agents may be developed which will be free of serious side effects, but the same statement holds true. For those acting on the mid-brain, of which many will be discovered, now that the door of specific action has been opened by reserpine and chlorpromazine, no agent can be more effective than the relative influence which the mid-brain bears to the total picture It is our belief that reversal and, perhaps, eventual cure can be only accomplished by drugs which will do what hydralazine does basically. Therefore, much time and effort must be spent to understand its fundamental actions. Sympathetic nerve blockade alone will be limited to mild stages, but severe cases need a double-barreled approach. The day when one specific drug will control all cases without careful supervision is far distant.
CONCLUDING REMARKS: Modern antihypertensive drugs require intelligent handling by both physician and patient. When so employed, the results are usually gratifying to the patient. As a first approximation of specific treatment, they are the best we have. In spite of our overstressing their toxicities, actually they are much less hazardous than some popular drugs and their use is well-justified by the seriousness of the disease which they can control. Fatalities due to the drugs themselves are rare. Their side effects which vary with their potencies are sometimes distressing but seldom require discontinuation. There are enough drugs now available to control the hypertension and promote longevity of almost any patient who wants to be treated and will submit to therapeutic inconveniences.
